Study Stopped
logistical issues
Intelligent Monitoring to Predict Atrial Fibrillation
NOTE-AF
1 other identifier
observational
1,200
1 country
2
Brief Summary
Atrial Fibrillation (AF) is the commonest arrhythmia worldwide, affects 5% of people over the age of 65 and increases the risk of stroke and heart failure. The investigators aim to detect clinical and subclinical episodes of atrial fibrillation lasting \>30 seconds to develop risk prediction models to identify patients at high risk for ischaemic stroke.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Sep 2024
Longer than P75 for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 12, 2024
CompletedFirst Posted
Study publicly available on registry
September 19, 2024
CompletedStudy Start
First participant enrolled
September 23, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 31, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
August 1, 2028
September 15, 2025
June 1, 2025
3.9 years
September 12, 2024
September 8, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
To determine the incidence of clinical and subclinical episodes of AF in acutely unwell patients and to generate data for the development and validation of virtual twins and clinical decision support tools.
1\) Number of participants with device detected AF lasting greater than 30 seconds
48 months
To determine the incidence of clinical and subclinical episodes of AF in acutely unwell patients and to generate data for the development and validation of virtual twins and clinical decision support tools.
Number of episodes of AF and duration of each AF episode
48 months
Secondary Outcomes (18)
Length of hospital stay
48 months
Hospital readmissions within 90 days
48 months
Recurrence of AF episodes
48 months
Hospital and 90-day Mortality
48 months
Time spent in AF
48 months
- +13 more secondary outcomes
Study Arms (7)
Patients admitted or referred to Critical Care (NOTE-AF ICU)
Patients admitted or referred to Critical Care
Patients admitted to hospital with acute heart failure (NOTE-AF HF)
Patients admitted to hospital with acute heart failure
Patients admitted to Emergency Services with sepsis or infection (NOTE-AF Sepsis)
Patients admitted to Emergency Services with sepsis or infection
Patients post upper gastrointestinal surgery (NOTE-AF PULSE-GI)
Patients post upper gastrointestinal surgery
Patients post vascular interventions (NOTE-AF Vasc)
Patients post vascular interventions
Patients with acute respiratory failure (NOTE-AF Resp)
Patients with acute respiratory failure
Patients admitted after acute stroke (NOTE-AF stroke)
Patients admitted after acute stroke
Interventions
The investigators will collect data in patients at high risk of atrial fibrillation (AF) without a known history of AF to determine clinical predicators of AF. This data will be used to generate virtual digital twins to to predict clinical and subclinical episodes of AF
Eligibility Criteria
Patients admitted to hospital with a variety of medical conditions
You may qualify if:
- Adult patients ≥50 years
- Estimated risk of developing new episodes of AF greater than 5%
- Sinus rhythm at presentation
- One of the following acute conditions:
- Patients admitted or referred to Critical Care (NOTE-AF ICU)
- Patients admitted to hospital with acute heart failure (NOTE-AF HF)
- Patients admitted to Emergency Services with sepsis or infection (NOTE-AF Sepsis)
- Patients post upper gastrointestinal surgery (NOTE-AF PULSE-GI)
- Patients post vascular interventions (NOTE-AF Vasc)
- Patients with acute respiratory failure (NOTE-AF Resp)
- Patients admitted after acute stroke (NOTE-AF stroke)
You may not qualify if:
- Atrial fibrillation or atrial flutter at the time of screening
- Patients in atrial fibrillation or atrial flutter at time of preoperative assessment or admission to hospital
- Paced cardiac rhythm
- Inability to obtain consent
- Allergy to plaster or silicone
- Expected hospital stay less than 48 hours
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Liverpool University Hospitals NHS Foundation Trustlead
- University of Copenhagencollaborator
- Isansys Lifecare LTDcollaborator
- University of Liverpoolcollaborator
- Liverpool John Moores Universitycollaborator
Study Sites (2)
Liverpool university foundation trust
Liverpool, United Kingdom
Liverpool University hospital Foundation trust
Liverpool, United Kingdom
Related Publications (1)
Essa H, Johnston B, Lip GYH, Ortega-Martorell S, Williams K, Welters ID; TARGET Consortium. Intelligent monitoring to predict atrial fibrillation (NOTE-AF): clinical study 1 for the 'Health virtual twins for the personalised management of stroke related to atrial fibrillation (TARGET)' project - a protocol for a prospective cohort analysis. BMJ Open. 2026 Jan 3;16(1):e099658. doi: 10.1136/bmjopen-2025-099658.
PMID: 41485778DERIVED
Biospecimen
Blood samples
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER GOV
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 12, 2024
First Posted
September 19, 2024
Study Start
September 23, 2024
Primary Completion (Estimated)
July 31, 2028
Study Completion (Estimated)
August 1, 2028
Last Updated
September 15, 2025
Record last verified: 2025-06